

INVESTOR WEBINAR PRESENTATION

Perth, Australia; 23 May, 2025 - Argenica Therapeutics Limited (ASX:AGN) ("AGN" or the Company) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on **Monday, May 26, 2025, 9:00am AWST/ 11:00am AEST.**

CEO & Managing Director Dr Liz Dallimore will discuss the latest company Investor Presentation highlighting what success will look like in the Phase 2 Clinical Trial in Acute Ischaemic Stroke and will participate in a live Q&A.

This webinar can be viewed live via zoom & you register for FREE via the link below.

Webinar Details:

Date: Monday 26 May

Time: **11:00am** AEST (Sydney/Melbourne), **9:00am** AWST (Perth)

Webinar Link: https://us06web.zoom.us/webinar/register/WN_T7uLzA8rQR6LIGX3983McQ

This announcement has been approved for release by the Managing Director.

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now completed dosing in a Phase 2 clinical trial in ischaemic stroke patients, and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.